Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oreongsan is a traditional East Asian herbal medicine consisting of five ingredients: Polyporus, Alismatis Rhizoma, Atractylodis Rhizoma, Poria, and Cinnamomi Cortex Spissus[1][2][3]. It is primarily prescribed for its diuretic ("isu") effect to regulate water balance and has historically been used for symptoms such as thirst, diminished urination, edema, hangover, and diarrhea[1]. In recent clinical use, Oreongsan is administered as an adjunctive therapy in patients with chronic subdural hematoma (CSDH), particularly to reduce the recurrence of hematoma after surgical intervention[1][2][3]. Its mechanism involves inhibition of aquaporin-4 and aquaporin-1 water channels in the outer membrane of CSDH, preventing fluid inflow into the hematoma[1][2][3][6]. This anti-edematous and anti-inflammatory activity is hypothesized to underlie its clinical effects in both neuro- and cardiovascular indications[4]. Evidence from meta-analyses suggests a statistically significant reduction in CSDH recurrence when Oreongsan is prescribed postoperatively, with a favorable safety profile[3]. The agent is administered orally, typically 2.5–5g, divided into doses per day as per the formulation TJ-17[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oreongsan.